529 results on '"Windyga J"'
Search Results
2. OC 14.1 Phase 3 Prospective, Randomized, Controlled, Open-Label, Multicenter, Crossover Study of Recombinant ADAMTS13 in Patients with Congenital Thrombotic Thrombocytopenic Purpura
3. OC 59.1 Concizumab Prophylaxis in Patients with Haemophilia A or B without Inhibitors: Efficacy and Safety Results from the Primary Analysis of the Phase 3 Explorer8 Study
4. OC 14.2 Pharmacokinetic Characteristics of ADAMTS13 in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Interim Results from a Phase 3 Randomized, Controlled, Open-Label, Crossover Study
5. OC 14.4 Recombinant ADAMTS13 Prophylaxis in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Interim Analysis from Phase 3B Continuation Study
6. PB1229 Haemostatic Control with Recombinant Porcine Factor VIII in Acquired Haemophilia A
7. PB1282 Real-World Unmet Needs of Adult Patients with Severe Hemophilia A without Inhibitors in Poland: How to Select the Optimal Therapy?
8. Pain relief with Eptacog beta in haemophilia patients with inhibitors
9. Emicizumab prophylaxis for the treatment of people with moderate or mild Hemophilia A without Factor VIII inhibitors: results from the primary analysis of the HAVEN 6 study
10. Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity
11. Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa
12. Detection of Factor VIII-Specific Memory B Cells in Patients with Hemophilia A and Factor VIII Inhibitors
13. Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey
14. PK‐guided personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in adults with severe haemophilia A
15. Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series
16. Outcome measures in European patients with haemophilia: Survey of implementation in routine clinical practice, perception of relevance and recommendations by European treaters in the EHTSB
17. Safety and efficacy of BAY 81–8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme
18. SAFETY AND EFFECTIVENESS OF ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE (APCC) MONOTHERAPY IN PATIENTS WITH HEMOPHILIA AND INHIBITORS (PWHI) UNDERGOING SURGERY: A SYSTEMATIC REVIEW AND META-ANALYSIS
19. Practical aspects of DDAVP use in patients with von Willebrand Disease undergoing invasive procedures: a European survey
20. Determinants of inhibitor development in previously treated hemophilia A patients: OR144
21. Safety, efficacy and pharmacokinetics of a recombinant von willebrand factor in patients with severe von willebrand disease: a prospective clinical trial: OR088
22. Traitement de l’hémophilie - Défis actuels et futurs: Rapport basé sur les présentations faites durant le symposium satellite sponsorisé par Bayer Schering Pharma dans le cadre du Consortium Européen sur l’Hémophilie, Septembre 2008 – Dublin
23. SAFETY AND EFFECTIVENESS OF ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE (APCC) MONOTHERAPY IN PATIENTS WITH HEMOPHILIA AND INHIBITORS (PWHI) UNDERGOING SURGERY: A SYSTEMATIC REVIEW AND META-ANALYSIS
24. Total elbow arthroplasty in patient with severe von Willebrand disease
25. Efficacy and safety of a recombinant factor IX (Bax326)a in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study
26. Investigating determinants of inhbitor development to factor VIII molecules in previously treated hemophilia A patients: PCI14
27. Improvement in health-related quality of life with recombinant factor IX prophylaxis in severe or moderately severe haemophilia B patients: results from the BAX326 Pivotal Study
28. Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS
29. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B
30. Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study
31. Course of pregnancy, labour and perioperative management of a patient with Bernard-Soulier Syndrome - case report and literature review: PO 356
32. Mutation analysis in patients with decreased fibrinogen level: PB 4.74–5
33. A case of protein S deficiency caused by compound heterozygous mutations in PROS1 gene: PB 3.67–4
34. Efficacy and safety of a novel rFIX (BAX326): phase III study in previously treated patients with severe or moderately severe hemophilia B undergoing surgical or other invasive procedures: PB 3.49–4
35. Prospective study of a novel recombinant factor IX in previously treated patients with hemophilia B: PB 3.49.6
36. European Haemophilia Network (EUHANET): PB 3.37–2
37. Improvement in health-related quality of life with recombinant factor IX prophylaxis in moderatelysevere or severe hemophilia B patients: results from the BAX326 pivotal study: PB 1.39–3
38. Multicentre, randomised, double-blinded, active-controlled, cross-over phase 3 trial on safety and efficacy of rFVIIa analogue (vatreptacog alfa) in haemophilia patients with inhibitors (adept™2): OC 83.2
39. Management of factor VII-deficient patients undergoing joint surgeries – preliminary results of locally developed treatment regimen
40. von Willebrandʼs disease: a report from a meeting in the Åland islands
41. Results of long-term prophylaxis in patients with factor XIII (FXIII) deficiency: PO-TU-275
42. Molecular analysis and clinical course of factor XI (FXI) deficiency in twelve Polish families: PO-TU-274
43. Sclerotherapy in secondary prophylaxis of esophageal variceal bleeding in hemophilia patients: PO-TU-142
44. ITI in Adult Hemophilia A Patients with Long-Lasting FVIII Inhibitors: Single-Centre Experience: PO-WE-144
45. Short and long-term management of haemophilia A patient requiring heart valve surgery
46. Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels from a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII: PO-WE-061
47. Safe concurrent use of intravenous or oral tranexamic acid and aPCC in patients with hemophilia complicated by high-titer inhibitors: PO-WE-036
48. Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia
49. Recommendations for assessment, monitoring and follow-up of patients with haemophilia
50. Clinical and laboratory results from adeptTM 1, a phase 2 trial investigating the use of recombinant activated FVII analogue in congenital haemophilia patients with inhibitors: O-WE-029
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.